Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.Intern Med. 2022 Jun 15; 61(12):1891-1895.IM
Abstract
Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.
Links
MeSH
Pub Type(s)
Case Reports
Journal Article
Language
eng
PubMed ID
35400701
Citation
Baba, Yuta, et al. "Successful Treatment of Immune Thrombocytopenic Purpura With Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination." Internal Medicine (Tokyo, Japan), vol. 61, no. 12, 2022, pp. 1891-1895.
Baba Y, Sakai H, Kabasawa N, et al. Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination. Intern Med. 2022;61(12):1891-1895.
Baba, Y., Sakai, H., Kabasawa, N., & Harada, H. (2022). Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination. Internal Medicine (Tokyo, Japan), 61(12), 1891-1895. https://doi.org/10.2169/internalmedicine.9199-21
Baba Y, et al. Successful Treatment of Immune Thrombocytopenic Purpura With Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination. Intern Med. 2022 Jun 15;61(12):1891-1895. PubMed PMID: 35400701.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.
AU - Baba,Yuta,
AU - Sakai,Hirotaka,
AU - Kabasawa,Nobuyuki,
AU - Harada,Hiroshi,
Y1 - 2022/04/09/
PY - 2022/4/12/pubmed
PY - 2022/6/18/medline
PY - 2022/4/11/entrez
KW - SARS-CoV-2 vaccine
KW - bleeding
KW - immune thrombocytopenic purpura
SP - 1891
EP - 1895
JF - Internal medicine (Tokyo, Japan)
JO - Intern Med
VL - 61
IS - 12
N2 - Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.
SN - 1349-7235
UR - https://www.unboundmedicine.com/medline/citation/35400701/Successful_Treatment_of_Immune_Thrombocytopenic_Purpura_with_Intracranial_Hemorrhaging_and_Duodenal_Bleeding_Following_SARS_CoV_2_Vaccination_
DB - PRIME
DP - Unbound Medicine
ER -